Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing services that support robust regulatory pathways without compromising quality or operational discipline. Through our European partnership with Histocell and its EMA-authorized facility in Bilbao, Spain, together with REPROCELL’s U.S. GMP site in Beltsville, Maryland, we offer a dual-site manufacturing network aligned with FDA, EMA, and PMDA expectations.
This infrastructure provides the scale, regulatory alignment, and global flexibility needed for allogeneic therapy programs moving to clinical translation without the excessive costs often linked to iPSC GMP manufacturing.
REPROCELL manages the entire iPSC workflow in-house: From sourcing donors and generating iPSC lines using its own proprietary reprogramming technology to performing clinical gene editing and producing GMP MCBs and Working Cell Banks (WCB). By keeping every step under a single organization, REPROCELL eliminates the handoffs common in multi-vendor setups, and avoids the delays, inconsistencies, and quality risks those transitions create.
This fully integrated set-up at REPROCELL ensures complete traceability of every cell line and delivers a consistent, regulatory-ready starting point for downstream development, whether for research, preclinical studies, or future therapeutic programs.
In short, REPROCELL functions as a true one-stop stem cell biotech, unifying the entire iPSC value chain under a single, dependable partner.
GMP iPSC MCB Manufacturing Through Our European Partner – Histocell
Histocell is an authorized GMP‑ATMP manufacturing facility capable of producing various clinical‑grade cell therapies under EMA‑compliant GMP. All cell-based GMP bank processes are accredited by AEMPS and operated under EMA guidelines, fully supported with:
- Donor traceability
- Release testing & batch records
- Regulatory documentation packages for CTA & IND Submissions
Histocell’s 800 m² state-of-the-art facility is EMA-registered, has produced over 350 GMP batches, and contributed to treating ~300 patients with ATMPs globally.
Through our partnership with the European GMP CDMO Histocell in Spain, REPROCELL offers a full-service platform for manufacturing GMP iPSC MCBs using our StemRNA™ Clinical iPSCs Clones.
From donor screening and footprint-free iPSC generation at REPROCELL to GMP MCB/WCB production at Histocell, this collaboration delivers regulatory-aligned, scalable manufacturing across European, U.S., and Japanese markets allowing therapy developers to focus on clinical translation with confidence.
GMP iPSC MCB Manufacturing At REPROCELL U.S. Facility
For cell therapy developers preferring U.S. based manufacturing, REPROCELL provides GMP iPSC MCB generation at our fully operational GMP-compliant manufacturing facility, located in Beltsville, MD. The site utilizes a state-of-the-art closed-system cell culture platform to deliver robust MCB production, minimize contamination risk, and accelerate turnaround time.
From donor recruitment and footprint-free RNA reprogramming to regulatory-aligned screening, all processes are conducted under FDA, EMA, and PMDA standards. U.S. StemRNA Clinical Seed Clones used as a starting material for GMP manufacturing are supported by an active Drug Master File (DMF), facilitating regulatory alignment and streamlined IND submissions for clinical programs.
Upcoming GMP MCB Manufacturing Suite
With the recent award of a Manufacturing Assistance Grant from the Maryland Stem Cell Research Fund (MSCRF), REPROCELL USA is currently expanding its CDMO capabilities to launch a purpose-built clean-room suite for large-scale GMP MCB and WCB manufacturing of iPSCs and iPSC-derived mesenchymal stem cells (iMSCs) (Figure 1). This new infrastructure will enable integrated services – spanning allogeneic cell therapy production, GMP-grade differentiation, clinical gene-editing and WCB creation, under one roof, positioning REPROCELL as a leading CDMO partner for cell-therapy developers seeking scalable, regulatory-ready iPSC and iMSC MCB services.
Find out more:
- EU (Histocell): https://hubs.li/Q03SMwJz0 \
- US (REPROCELL USA): https://hubs.li/Q03SMtVL0
- Check out our StemRNA™ Clinical Seed Clones: https://hubs.li/Q03SMy770
Ready to discuss your project requirements? Simply complete our online inquiry form or send us an email at: info-emea@reprocell.com